Effectofischemiccompressiononmyofascialpainsyndrome:asystematicreviewandmeta-analysis

Myofascial pain syndrome (MPS) is a common musculoskeletal condition characterized by trigger points—taut, sensitive bands within muscles that cause local and referred pain when pressed or activated. It affects a substantial portion of patients with chronic pain, with prevalence estimates ranging from 9% to 85% depending on the population studied. Ischemic compression, also known as manual pressure release or trigger point release massage, is a widely used noninvasive manual therapy technique for treating MPS. It involves applying sustained pressure to a trigger point for 30–90 seconds, theoretically creating local ischemia followed by reperfusion that improves muscle metabolism.

Despite decades of use, the evidence base for ischemic compression's effectiveness on pain outcomes in MPS has been limited. A 2015 systematic review found moderate evidence for benefit but could not perform quantitative synthesis due to insufficient data. More recently, a meta-analysis examined range of motion outcomes but did not address pain—the primary symptom of MPS. This gap motivated the current comprehensive systematic review and meta-analysis focused specifically on pain-related outcomes.

The researchers conducted a systematic review and meta-analysis following PRISMA guidelines, registered with INPLASY. They searched five major databases (PubMed, Cochrane Library, Embase, Web of Science, and Ovid) from inception through January 2, 2022, for randomized controlled trials (RCTs) comparing ischemic compression to placebo, sham, or usual care interventions in patients with diagnosed MPS according to established Simon et al. criteria. Two independent reviewers screened literature, extracted data, and assessed study quality using the Cochrane Risk of Bias 2 (RoB 2) tool. The primary outcomes were pain measures, including pressure pain threshold (PPT)—an objective measure of pain tolerance—and self-reported pain intensity using visual analog scale (VAS) or numeric rating scale (NRS).

Standardized mean differences (SMD) with 95% confidence intervals were calculated using RevMan 5.3 software. Subgroup analyses were planned for active versus inactive controls, treatment duration, compression location, and sex. Sensitivity analyses were also planned.

Seventeen RCTs were included in the systematic review, with 15 RCTs providing sufficient data for meta-analysis. These studies were conducted across multiple countries including Turkey, Saudi Arabia, New Zealand, India, the USA, Iran, Egypt, Spain, Belgium, and Portugal. The studies involved various body locations, most commonly the upper trapezius and neck region.

For pressure pain threshold, 11 studies with 427 subjects demonstrated a statistically significant effect favoring ischemic compression over control at posttreatment (SMD 0.67, 95% CI [0.35, 0.98], P < 0.0001, I² = 59%). In subgroup analysis, there was no significant difference compared with active controls (SMD = 0.30, 95% CI [−0.01, 0.62], P = 0.06, I² = 20%), but a statistically significant difference compared with inactive controls (SMD = 0.99, 95% CI [0.61, 1.36], P < 0.00001, I² = 41%).

For self-reported pain intensity (VAS/NRS), 7 studies with 251 subjects showed no significant difference between ischemic compression and controls posttreatment (SMD = −0.22, 95% CI [−0.53, 0.09], P = 0.16, I² = 33%). Neither the active control subgroup (SMD = −0.13, 95% CI [−0.48, 0.21], P = 0.44, I² = 13%) nor the inactive control subgroup (SMD = −0.34, 95% CI [−0.97, 0.30], P = 0.30, I² = 58%) showed significant differences.

Publication bias was detected for the PPT outcome. No adverse events were reported in any included RCTs. Most studies lacked blinding of practitioners and/or patients. Quality assessment revealed methodological concerns, with most studies having some risk of bias domains, particularly around blinding.

The key finding is a disconnect between objective and subjective pain measures: ischemic compression improved pressure pain threshold (pain tolerance) but did not reduce self-reported pain intensity. This challenges common assumptions about how trigger point therapies work. The authors propose that ischemic compression may improve local muscle metabolism and reduce inflammatory mediators at the trigger point site, explaining the PPT improvement. However, it may not adequately address central sensitization—the heightened responsiveness of the central nervous system to pain signals that often develops in chronic pain conditions.

Since VAS/NRS reflects the brain's interpretation of pain rather than just peripheral tissue sensitivity, the lack of effect on self-reported pain suggests that ischemic compression alone may be insufficient for patients with established central sensitization.

For clinicians, this means ischemic compression may have a role in improving local tissue tolerance but should not be relied upon as a standalone treatment for pain reduction in MPS. Combining it with approaches that target central pain processing—such as education, graded exercise, or other modalities—may be more effective. The finding also raises fundamental questions about whether trigger points themselves are the primary driver of pain in MPS, or whether they represent one component of a more complex pain condition involving central nervous system changes.

For patients, this suggests that while ischemic compression may make muscles less tender to touch, it may not substantially change how much pain they actually experience day-to-day. Setting realistic expectations is important: this therapy might help with certain aspects of muscle sensitivity but is unlikely to be a complete solution for chronic myofascial pain.

The authors appropriately note significant limitations: small total participant numbers, short treatment durations (mostly under one week), lack of long-term follow-up, and absence of measures for daily functioning or quality of life. They call for large-scale RCTs with more subjects, longer durations, and longer follow-up periods to better understand ischemic compression's role in MPS management.